Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | C1S | P09871 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL271385 | 0.85 | L3MBTL1 (0.52) | ALDH1A1HPGDL3MBTL1 | |
| SCHEMBL28771843 | 0.85 | PARP1 (0.53) | PARP1ALDH1A1TP53HPGDC1S | |
| SCHEMBL1381245 | 0.82 | PARP1 (0.66) | PARP1ALDH1A1TP53HPGDC1S | |
| SCHEMBL27934182 | 0.81 | PARP1 (0.53) | PARP1ALDH1A1TP53HPGDC1S | |
| SCHEMBL2684848 | 0.79 | PARP1 (0.61) | PARP1ALDH1A1TP53HPGDC1S | |
| SCHEMBL29537403 | 0.79 | PARP1 (0.65) | PARP1ALDH1A1TP53HPGDC1S | |
| SCHEMBL5023 | 0.79 | PARP1 (0.65) | PARP1ALDH1A1TP53HPGDC1S | |
| SCHEMBL322248 | 0.78 | PARP1 (0.50) | PARP1ALDH1A1TP53HPGDSMN1; SMN2 | |
| SCHEMBL21312125 | 0.78 | C1S (0.59) | PARP1ALDH1A1TP53HPGDC1S | |
| SCHEMBL1137535 | 0.78 | CA12 (0.63) | PARP1ALDH1A1GAANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1015505-B1 | PRODUCTION OF PHOTOPOLYMERIZED POLYESTER HIGH INDEX OPHTHALMIC LENSES | SIGNET ARMORLITE INC (US) | 2005-03-09 | — | — | EP | claimed |
| EP-0783710-B1 | POLYESTER RESIN-BASED HIGH INDEX OPHTHALMIC LENSES HAVING IMPROVED OPTICAL UNIFORMITY AND/OR TINTABILITY | SIGNET ARMORLITE INC (US) | 2002-05-29 | — | — | EP | claimed |
| CN-109369637-B | Novel kojic acid derivative containing 1,3, 4-thiadiazole and application thereof | 湖南科技大学 | 2021-04-06 | — | — | CN | disclosed |
| CN-109369637-A | The novel derivative of kojic acid of one kind thiadiazoles containing 1,3,4- and its application | 湖南科技大学 | 2019-02-22 | — | — | CN | disclosed |
| CN-105566021-B | A kind of α, the preparation method of beta-unsaturated carboxylic acid class compound | 中国科学技术大学 | 2018-05-29 | — | — | CN | disclosed |
| US-8048893-B2 | Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them | AVENTIS PHARMA SA (FR) | 2011-11-01 | — | — | US | disclosed |
| US-20090170833-A1 | PYRAZOLYL DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS AS MEDICINAL PRODUCTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2009-07-02 | — | — | US | disclosed |
| US-7524838-B2 | Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. (FR) | 2009-04-28 | — | — | US | disclosed |
| US-7442702-B2 | Treatment of bone disorders; carboxy derivatives | PFIZER INC. (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1021410-B1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20050165005-A1 | Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. (FR) | 2005-07-28 | — | — | US | disclosed |
| US-6825360-B1 | Bicyclic aromatic compounds | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-11-30 | — | — | US | disclosed |
| US-20030135053-A1 | For use in human or veterinary conditions, that may be dermatological, rheumatic, respiratory, or cardiovascular and may be used in cosmetics | BERNARDON JEAN-MICHEL | 2003-07-17 | — | — | US | disclosed |
| US-20030060491-A1 | Bicyclic aromatic compounds | BERNARDON JEAN-MICHEL (FR) | 2003-03-27 | — | — | US | disclosed |
| US-6515021-B1 | Bicyclic aromatic compounds | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2003-02-04 | — | — | US | disclosed |
| US-6498172-B1 | (3-(((4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO)-METHYL) -PHENOXY)-ACETIC ACID OR SALT; TREATING SUCH AS OSTEOPOROSIS | PFIZER INC. | 2002-12-24 | — | — | US | disclosed |
| US-6147255-A | TOPICAL AND SYSTEMIC TREATMENT OF DERMATOLOGICAL COMPLAINTS ASSOCIATED WITH KERATINIZATION DISORDER WHICH HAS EFFECT ON DIFFERENTIATION AND ON PROLIFERATION | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2000-11-14 | — | — | US | disclosed |
| EP-1021410-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-1999019300-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 1999-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060491-A1 | Bicyclic aromatic compounds | MITF, TYR, PAH | PARP1 2795/4885ALDH1A1 154/4885TP53 1645/4885 |
| US-20090170833-A1 | PYRAZOLYL DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS AS MEDICINAL PRODUCTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | C1R, CBR3, C3AR1 | PARP1 4626/4885ALDH1A1 2487/4885TP53 2168/4885 |
| US-20030135053-A1 | For use in human or veterinary conditions, that may be dermatological, rheumatic, respiratory, or cardiovascular and may be used in cosmetics | MITF, TYR, PAH | PARP1 3341/4885ALDH1A1 29/4885TP53 2036/4885 |
| US-20050165005-A1 | Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them | C1R, CBR3, C3AR1 | PARP1 4628/4885ALDH1A1 2499/4885TP53 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.